Radical Transparency Bears Fruit: California Olive Ranch Earns Seed Oil Free Certification
CHICO, Calif.--(BUSINESS WIRE)--Rooted in innovation and radical transparency, California Olive Ranch has grown into the largest domestic grower of olives for Extra Virgin Olive Oil (EVOO) by challenging industry norms, ensuring the quality, authenticity, and integrity of their products for more than 20 years. As the first retail brand offering Extra Virgin Olive Oil to earn the Seed Oil Free Certified™ Seal, California Olive Ranch continues to elevate standards with certification across their full lineup of dressings, marinades, and avocado blend cooking oils.
'The Seed Oil Free Certified seal is a trusted indicator that our products meet the highest standards for transparency and quality. It reflects our commitment to offering products aligned with consumer values.' Mary Mori, VP of Product & Quality
Share
'We pride ourselves on going above and beyond by proudly disclosing place-of-origin, harvest season, and quality testing results on every bottle of our cold-pressed Extra Virgin Olive Oil,' said Mary Mori, VP of Product & Quality for California Olive Ranch. 'Seed Oil Free Certification guarantees customers who choose to avoid seed oils can confidently enjoy all our Extra Virgin Olive Oils, avocado blend, and vinaigrettes. It reflects our core value of radical transparency to continually verify all our products meet the highest standards of purity.'
Known for their robust quality assurance program, California Olive Ranch are the first producers of Extra Virgin Olive Oil (EVOO) to earn the Seed Oil Free Certified Seal, affirming that the brands' olive oils, avocado oil, flavored oils, vinaigrettes and marinades and other ingredients are free from seed oil adulteration and meet the highest quality standards.
'The Seed Oil Free Certified Seal offers verified assurance in a market where premium oils, especially extra virgin olive and avocado oils, are being sought out by consumers for their incredible flavor, health benefits, and heat stability,' said Jonathan Rubin, CEO and founder of the Seed Oil Free Alliance. 'California Olive Ranch has led the industry in innovation, sustainability, and quality assurance for decades. This dedication to what they call 'Radical Transparency' is why California Olive Ranch makes a perfect partner for Seed Oil Free Certification.'
The certification process included lab testing for purity and comprehensive third-party audits of California Olive Ranch's supply chain and formulation practices. All tests are aligned with globally recognized standards, including the International Olive Council (IOC), Codex Alimentarius, and the Food Chemicals Codex (FCC). These protocols ensure that every Seed Oil Free Certified product is free from contamination with adulterants such as soybean, canola, and corn oil. To become Seed Oil Free Certified, the brand reformulated certain sauces and dressings by replacing carrier oils that contained trace amounts of seed oil with MCT oil.
California Olive Ranch's commitment to purity, ingredient integrity, and consumer transparency is now represented with the Seed Oil Free Certified Seal (pictured). All California Olive Ranch and Lucini products bearing the Seed Oil Free Certified Seal can be found at seedoilfreecertified.com/product-finder and grocery stores nationwide.
California Olive Ranch
Lucini
Brands like California Olive Ranch, which do not emphasize health trends around seed oils, recognize the importance of transparency in light of modern dietary shifts. Refined seed oils, virtually absent before the 20th century, now supply over 20% of daily calories for many Americans. Consumers are seeking healthy cooking oil alternatives or avoiding seed oils entirely, driven by a desire for more traditional and less industrially processed ingredients in the foods they choose.
'We rigorously evaluate all of the products made from our own cold-pressed extra virgin olive oil and work closely with external certifying bodies like the Seed Oil Free Alliance because customers deserve to know they're buying the best,' said Mori. 'The Seed Oil Free Certified seal is a trusted indicator that our products meet the highest standards for transparency and quality. It reflects our commitment to offering products aligned with consumer values.'
Winner of over 260 awards at international tasting competitions, California Olive Ranch is the nation's largest producer of olives for extra virgin olive oil. As a leading innovator in olive cultivation, harvesting, and milling, the company has remained dedicated to environmental stewardship, fanatical about quality, and operated with radical transparency since its founding in 1998. In addition to Seed Oil Free Certified, the company maintains several third-party certifications that meet the industry's highest standards, including Certified Extra Virgin, Non-GMO Project Verified, USDA Organic, and Certified Regenerative by AGW.
About California Olive Ranch
Founded in 1998, California Olive Ranch is the largest grower of olives for extra virgin olive oil in the state of California. With a history of blending tradition with innovation in the cultivating, harvesting and milling of olives, the company is highly regarded for its award-winning, high quality and approachable olive oil. Selling a variety of oils, sauces, dressings and vinegars under the California Olive Ranch® and Lucini® brands, the company is committed to transparency and sustainable practices in both growing, and packaging, all while offering artisan quality at an accessible price point. California Olive Ranch also partners with numerous family farmers throughout the state of California as well as around the world to produce its products. These partners share the same high standards, sustainable farming practices and premium production methods. For more information, please visit www.californiaoliveranch.com.
About Seed Oil Free Certified™
The Seed Oil Free Alliance is a third-party certifying organization behind the world's first Seed Oil Free Certified™ Seal for qualifying food and consumer products. The Seed Oil Free Certified Seal guarantees that certified products have undergone auditing and independent laboratory testing to ensure the purity of added oils and refined fat ingredients. Supporting the Seed Oil Free Alliance in its mission to advance the availability of seed-oil-free food options through trust, transparency, and education is an advisory panel of public health and nutrition experts, led by Dr. Andrew Weil. More information can be found at seedoilfreecertified.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 hours ago
- Business Wire
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass.--(BUSINESS WIRE)-- SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; 'Modalis'), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM ® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM ® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. 'SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD,' stated Eva Chin, Executive Director of SOLVE FSHD. 'SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials.' 'We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103,' said Haru Morita, CEO of Modalis. 'This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM ® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM ® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD.' About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM ® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit
Business Wire
a day ago
- Business Wire
ABL Investors Have Opportunity to Join Abacus Global Management, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abacus Global Management, Inc. ('Abacus' or 'the Company') (NASDAQ: ABL) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Abacus is the subject of a report issued by Morpheus Research on June 4, 2025, titled: 'Abacus Global Management: This $794 Million SPAC Is Yet Another Life Settlements Accounting Scheme Manufacturing Fake Revenue by Systematically Underestimating When People Will Die.' According to the report, the Company changed its portfolio valuation methodology to make it appear more profitable than it actually is. The report also alleges that the Company uses unusual methodologies to calculate life expectancy estimates and its co-founders have 'red flags' in their past. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
